Editorial: Is adequate relief fatally flawed or adequate as an end point in irritable bowel syndrome

American Journal of Gastroenterology

Volumn 104, Issue 4, 2009, Pages 920-922

  Camilleri, Michael ^a  

^a Clinical Enteric Neuroscience Translational and Epidemiological Research Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; ANTIDEPRESSANT AGENT; ASIMADOLINE; CILANSETRON; DEXTOFISOPAM; PLACEBO; TEGASEROD; TOFISOPAM; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANALGESIA; BEHAVIOR THERAPY; CLINICAL ASSESSMENT; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; IRRITABLE COLON; OBSERVATIONAL STUDY; PATIENT CARE; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL ANALOG SCALE; ACUPUNCTURE; IRRITABLE BOWEL SYNDROME; PAIN MEASUREMENT; PROCEDURES; QUESTIONNAIRE;

ACUPUNCTURE THERAPY; HUMANS; IRRITABLE BOWEL SYNDROME; PAIN MEASUREMENT; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 65449123189     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.20     Document Type: Review

References (22)

1. U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research; U.S. Department of Health and Human Services FDA Center for Biologtes Evaluatton and Research; U.S. Department of Health and Human Services FDA Center for Devices and Radiologteal Health. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qua! Ltfe Outcomes 2006;4:79.
2. Camilleri M, Cbang L. Challenges to the therapeutic ptpe!ine for irritable bowel syndrome: end points and regulatory hurdles. Gastroenterology 2008;135:1877-91.
3. Bijkerk CJ, de Wit NJ, Muris JWM et al. Outcome measures tn IBS. Am J Gastroenterol 2003;98:122-7.
4. Camilleri M, Mangel AW, Fehnel SE et al. Primary endpoints for IBS trials: a revtew of performance of endpoints. Clin Gastroenterol Hepatol 2007;5:534-40.
5. Mangel AW, Hahn BA, Heath AT et al. Adequate relief as an endpoint in clinical trials in irritable bowel syndrome. J Int Med Res 1998;26:76-81.
6. El-Serag HB, Olden K, Bjorkman D. Health-related quality of life among persons wtth irritable bowel syndrome: a systematic revtew. Altment Pharmacol Ther 2002;16:1171-85.
7. Whitehead WE, Palsson OS, Levy RL et al. Reports of "satisfactory relief" by lBS patients reeetvtng usual medical care are confounded by baseline symptom severity and do not accurately relleet symptom improvement. Am J Gastroenterol 2006;10l:1057-65.
8. Francis CY, Morris I, Whorwell PJ. The irritable bowel severity scoring system: a stmple method of monitoring irritable bowel syndrome and tts progress. Altment Pharmaeol Ther 1997;11:395-402.
9. Design of Treatment Trials Committee Irvine EJ, Whitehead WE, Chey WD et al. Design of treatment trials for functional gastrointestinal disorders. Gastroenterology 2006;130:1538-51.
10. Passos MCF, Lembo AJ, Conboy LA et al. Adequate relief in a treatment trial with lBS patients: a prospective assessment. Am J Gastroenterol 2009;104:912-9 (this issue).
11. Ameen VZ, Heath AT, Mesorley D et al. Global measure of adequate relief predicts clinically important difference in pain and is independent of baseline pain sex erity in lBS. Gastroenterology 2007;132:A140.
12. Camilleri M, Mayer EA, Drossman DA et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmaeol Ther 1999;13:1149-59.
13. Camilleri M, Northcutt AR, Kong S et al. Etheacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Laneet 2000;355:1035-40.
14. Camilleri M, Chey WY, Mayer EA et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med 2001;161:1733-40.
15. Miner PBJ, Pruitt RE, Carter F. Cilansetron is etheaeious in treating diarrheal symptoms in irritable howe! syndrome with diarrhea predominance (IBS-D) over 3 months. Gastroenterology 2004;128:A29.
16. Bradette M, Moennikes H, Carter F et al. Cilansetron in irritable bowel syndrome witb diarrhoea predominance (IBS-D): etheacy and safety hi a 6 month global stud). Gastroenterology 2004;126:A42.
17. Coremans G, Clouse RE, Carter F et al. Cilansetron, a novel 5-HT3 antagonist demonstrated etheaey in males with irritable bowel syndrome with diarrhoea-predominance (IBS-D). Gastroenterology 2004;126:A643.
18. Kellow J, Lee DY, Chang FY et al. An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the etheaey, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003;52:671-6.
19. Nyhlin H, Bang C, Elsborg L et al. A double-blind, placebo-controlled, randomized study to evaluate the etheaey, safety and tolerability of tegaserod in patients with irritable bowel syndrome. Scand J Gastroenterol 2004;39:119-26.
20. Tack J, Muller-Lissner S, Bytzer P et al. A randomised controlled trial assessing the etheaey and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation. Gut 2005;54:1707-13.
21. Leventer SM, Raudihaugh K, Frissora CL et al. Clinical trial: dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome. Aliment Pharmacol Ther 2008;27:197-206.
22. Lackner JM, Jaecard J, Krasner SS et al. Self-administered cognitive behavior therapy for moderate to severe irritable bowel syndrome: clinical etheaey, tolerability, feasibility. Cliii Gastroenterol Hepatol 2008;6:899-906.